Esperion Therapeutics (ESPR) Stock Forecast, Price & News

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

Is Esperion Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics or view top-rated stocks.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Esperion Therapeutics.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its quarterly earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.11. The biopharmaceutical company earned $18.84 million during the quarter, compared to the consensus estimate of $15.41 million. The company's revenue was up 136.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.50) EPS.
View Esperion Therapeutics' earnings history.

What price target have analysts set for ESPR?

8 Wall Street analysts have issued 12 month price objectives for Esperion Therapeutics' shares. Their forecasts range from $5.00 to $90.00. On average, they anticipate Esperion Therapeutics' stock price to reach $21.11 in the next twelve months. This suggests a possible upside of 264.0% from the stock's current price.
View analysts' price targets for Esperion Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:

• Mr. Sheldon L. Koenig, Pres, CEO & Director (Age 56, Pay $728.91k)
• Dr. Joanne Micale Foody FACC, M.D., Chief Medical Officer (Age 57, Pay $471.86k)
• Dr. Kenneth J. Fiorelli, Chief Technical Operations Officer
• Mr. Benjamin Church, Head of Corp. Communications & Investor Relations
• Mr. Benjamin O. Looker, Gen. Counsel & Corp. Sec. (Age 40)
• Mr. Keith F. Lenden, VP of Corp. Devel. & Strategy (Age 49)
• Ms. Betty Jean Swartz, Chief Strategy Officer
• Mr. Eric J. Warren R.Ph., Chief Commercial Officer (Age 49)
• Ms. April Seiler, Sr. Director of Project Management
• Roberta Peterson, Sr. Director of National Accounts

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Who are some of Esperion Therapeutics' key competitors?

Some companies that are related to Esperion Therapeutics include Xenon Pharmaceuticals (XENE), Arcus Biosciences (RCUS), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Sierra Oncology (SRRA), Prothena (PRTA), Cryoport (CYRX), IVERIC bio (ISEE), 23andMe (ME), Celularity (CELU), BELLUS Health (BLUSF), Madrigal Pharmaceuticals (MDGL), Zentalis Pharmaceuticals (ZNTL), MannKind (MNKD) and Prometheus Biosciences (RXDX).
View all of ESPR's competitors.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (12.93%), Deep Track Capital LP (9.52%), Vanguard Group Inc. (7.13%), Bellevue Group AG (6.82%), Paradigm Biocapital Advisors LP (1.84%) and Rhenman & Partners Asset Management AB (1.56%). Company insiders that own Esperion Therapeutics stock include Eric Warren, Sheldon L Koenig and Target N V Biotech.
View institutional ownership trends for Esperion Therapeutics.

Which major investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Walleye Trading LLC, State Street Corp, Monaco Asset Management SAM, PDT Partners LLC, UBS Group AG, Group One Trading L.P., and HAP Trading LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Eric Warren, and Sheldon L Koenig.
View insider buying and selling activity for Esperion Therapeutics or view top insider-selling stocks.

Which major investors are buying Esperion Therapeutics stock?

ESPR stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Vanguard Group Inc., Renaissance Technologies LLC, Deep Track Capital LP, Paradigm Biocapital Advisors LP, Northern Trust Corp, Bank of New York Mellon Corp, and Goldman Sachs Group Inc..
View insider buying and selling activity for Esperion Therapeutics or or view top insider-buying stocks.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $5.80.

How much money does Esperion Therapeutics make?

Esperion Therapeutics has a market capitalization of $365.44 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269.11 million in net income (profit) each year or ($6.99) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

Esperion Therapeutics employs 218 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at [email protected].